Lexaria Bioscience Corp. (NASDAQ: LEXX) announced the extension of its Material Transfer Agreement (MTA) with an undisclosed pharmaceutical company, referred to as PharmaCO, through December 31, 2026. The original MTA, signed on August 30, 2024, was designed to evaluate Lexaria’s patented DehydraTECH drug delivery platform in a pre-clinical setting. The extension allows additional time for PharmaCO to receive and review Lexaria’s 2026 research and development results related to GLP-1 drugs, a class of therapies used for diabetes and obesity.
The extended agreement keeps the temporary exclusive license active and enables further strategic planning discussions with PharmaCO’s human clinical and business development teams. This move signals continued interest from the pharmaceutical partner in Lexaria’s technology, which has shown promise in improving oral drug delivery.
Over the past 12 months, Lexaria has made significant progress in its GLP-1 development program. The company is currently conducting three studies: Human Study #7, Animal Study #1, and Animal Study #2. All are focused on the GLP-1 sector and are designed to provide comprehensive evidence to support additional collaboration and potential licensing of DehydraTECH. These studies are fully funded with existing corporate resources, and results are expected in the third and fourth quarters of 2026.
Lexaria’s DehydraTECH technology is a patented drug delivery formulation and processing platform that improves the way drugs enter the bloodstream through oral delivery. The platform has repeatedly demonstrated the ability to increase bio-absorption, reduce side effects, and deliver some drugs more effectively across the blood-brain barrier. The company operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide.
For business leaders, the extension of this MTA underscores the growing interest in advanced drug delivery technologies that can enhance the efficacy of GLP-1 therapies. The global GLP-1 receptor agonist market is expanding rapidly, driven by the rising prevalence of type 2 diabetes and obesity. Lexaria’s technology could potentially offer a competitive edge by enabling oral delivery of drugs that are typically administered via injection, improving patient compliance and convenience.
However, the company cautions that forward-looking statements involve risks and uncertainties. Factors such as regulatory approvals, competition, and scientific discovery could affect actual outcomes. No assurance can be given that the postulated uses or benefits of DehydraTECH will be realized. The company disclaims any obligation to update forward-looking statements except as required by law.
More information about Lexaria and DehydraTECH is available at www.lexariabioscience.com. The original press release can be viewed on NewMediaWire.
